Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54

Lung Cancer Clinical Trial

Official title:

Lung B.A.S.E.S 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Assessing Incidence and Stage of Lung Cancer Diagnosis in Subjects Ages 40-54 With a 30 Pack Year History or More Within North and South Carolina

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04577599
• Other study ID #: IRB00081444
• Secondary ID: 00045190LCI-LUN-
• Status: Recruiting
• Phase: N/A
• Start date: January 7, 2021
• Est. completion date: October 31, 2025

Study information

• Verified date: January 2024
• Source: Wake Forest University Health Sciences
• Contact: Darcy Doege, RN
• Phone: 913-424-6431
• Email: Darcy.Doege[@]atriumhealth.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Low-dose CT Screening has been shown in two large trials in the United States (NLST) and Europe (NELSON) to increase overall survival in subjects 55 years of age and older with a strong smoking history. Unfortunately, in both North Carolina (NC) and South Carolina (SC), subjects are found to have the above referenced smoking history prior to reaching the minimum age in these studies. This study is aimed at decreasing the minimum age of screening in a high-risk population.

Description:

The primary objective of this study is to evaluate the lung cancer diagnosis rate in individuals 40-54 years of age at their first screening (T0) with mobile low-dose CT. Secondary objectives include evaluating the lung cancer diagnosis rate in individuals 40-54 years of age at subsequent screening visits (T1 and T2); evaluating the positive screening rate at T0, T1, and T2; evaluating the impact of baseline demographic (including insurance status), socioeconomic, and healthcare-related factors on lung cancer rates and positive screening rates; and summarizing the incidence rate of all types of cancer found with low-dose lung CT during lung cancer screening. Enrollment will continue until 174 subjects are identified in the evaluable population with a total of 1160 subjects anticipated to be enrolled and screened.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1160
• Est. completion date: October 31, 2025
• Est. primary completion date: October 31, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 40 Years to 54 Years

Eligibility

Inclusion Criteria:

• Subject must meet all the following applicable inclusion criteria to participate in this study:

1. Written informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.

2. Age 40-54 years at the time of consent.

3. A positive smoking history of greater/equal to 30 pack years and they are either currently smoking or have quit within the last 15 years.

4. Ability to read and understand the English and/or Spanish language.

5. Ability to understand and comply with study procedures for the entire length of the study.

Exclusion Criteria:

• Subjects meeting any of the criteria below may not participate in the study:

1. Known diagnosis of lung cancer in the past 5 years.

2. Any known contraindication to having a low-dose CT Scan.

3. Known pregnancy.

Related Conditions & MeSH terms

• Lung Cancer
• Lung Neoplasms

Intervention

Other:
• Mobile Low-dose Computed Tomography (LDCT) Screening
Low Dose CT Scan of the Chest

Locations

Country	Name	City	State
United States	Levine Cancer Institute	Charlotte	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
Wake Forest University Health Sciences	Leon Levine Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Lung cancer diagnosis rate in individuals 40-54 years of age at their first screening (T0) with mobile low-dose CT.	The lung cancer diagnosis variable will be determined for each subject as a binary variable indicating whether or not the subject's T0 screening results in a diagnosis of lung cancer.	1 day
Secondary	Lung cancer diagnosis rate in individuals 40-54 years of age at subsequent screening visits (T1 and T2)	The lung cancer diagnosis variable will be determined for each subject as a binary variable indicating whether or not the subject's T1 and T2 screening results in a diagnosis of lung cancer.	up to 24 months
Secondary	Positive screening rate at T0, T1, and T2	The positive screening variable at T0, T1 and at T2 will be determined for each subject as a binary variable indicating whether or not the subject's screening results indicate a Lung RADS of 3 or 4.	up to 24 months
Secondary	Impact of baseline demographic (including insurance status), socioeconomic, and healthcare-related factors on lung cancer rates and positive screening rates	All binary outcomes will be analyzed using logistic regression models to evaluate the impact of baseline demographic, socioeconomic, and health care-related factors.	up to 24 months
Secondary	Incidence rate of all types of cancer found with low-dose lung CT during lung cancer screening	Incidental cancer diagnosis resulting from LDCT scan findings at T0, at T1, and at T2 will be captured for each subject including binary value of yes vs no for other cancer diagnosis, diagnosis date, type of cancer, and stage of disease.	up to 24 months